EVERYTHING ABOUT THE JOURNAL OF RHEUMATOLOGY

A randomized, double-blind, placebo controlled, section III clinical trial evaluated the efficacy and protection profile of adalimumab being a monotherapy in patients with RA who had failed to respond to csDMARDs [191]. The final results showed the two statistically significant advancement while in the illness activity and a fantastic basic safety